nodes	percent_of_prediction	percent_of_DWPC	metapath
Eletriptan—CYP2A6—esophageal cancer	0.371	0.468	CbGaD
Eletriptan—PTGS1—esophageal cancer	0.284	0.358	CbGaD
Eletriptan—ABCB1—esophageal cancer	0.138	0.174	CbGaD
Eletriptan—CYP2C9—Capecitabine—esophageal cancer	0.008	0.433	CbGbCtD
Eletriptan—CYP2C9—Cisplatin—esophageal cancer	0.00403	0.218	CbGbCtD
Eletriptan—ABCB1—Cisplatin—esophageal cancer	0.00391	0.212	CbGbCtD
Eletriptan—ABCB1—Methotrexate—esophageal cancer	0.00254	0.137	CbGbCtD
Eletriptan—HTR7—vagus nerve—esophageal cancer	0.000727	0.284	CbGeAlD
Eletriptan—Hiccups—Capecitabine—esophageal cancer	0.000527	0.00575	CcSEcCtD
Eletriptan—Blood pressure increased—Capecitabine—esophageal cancer	0.000527	0.00575	CcSEcCtD
Eletriptan—Stupor—Methotrexate—esophageal cancer	0.000526	0.00573	CcSEcCtD
Eletriptan—Depressed level of consciousness—Capecitabine—esophageal cancer	0.000509	0.00555	CcSEcCtD
Eletriptan—Candida infection—Capecitabine—esophageal cancer	0.000503	0.00549	CcSEcCtD
Eletriptan—Face oedema—Cisplatin—esophageal cancer	0.000501	0.00546	CcSEcCtD
Eletriptan—Gingivitis—Methotrexate—esophageal cancer	0.0005	0.00545	CcSEcCtD
Eletriptan—Abscess—Methotrexate—esophageal cancer	0.000496	0.00541	CcSEcCtD
Eletriptan—Neuropathy—Capecitabine—esophageal cancer	0.000495	0.0054	CcSEcCtD
Eletriptan—Dry eye—Capecitabine—esophageal cancer	0.000487	0.00531	CcSEcCtD
Eletriptan—Oesophagitis—Capecitabine—esophageal cancer	0.000482	0.00525	CcSEcCtD
Eletriptan—Urine output increased—Capecitabine—esophageal cancer	0.000477	0.0052	CcSEcCtD
Eletriptan—Cramp muscle—Cisplatin—esophageal cancer	0.000467	0.0051	CcSEcCtD
Eletriptan—Abnormal vision—Capecitabine—esophageal cancer	0.00046	0.00501	CcSEcCtD
Eletriptan—Mental disability—Capecitabine—esophageal cancer	0.000457	0.00499	CcSEcCtD
Eletriptan—Speech disorder—Methotrexate—esophageal cancer	0.000456	0.00497	CcSEcCtD
Eletriptan—Ear pain—Capecitabine—esophageal cancer	0.000448	0.00489	CcSEcCtD
Eletriptan—Sleep disorder—Capecitabine—esophageal cancer	0.000442	0.00482	CcSEcCtD
Eletriptan—Thrombophlebitis—Capecitabine—esophageal cancer	0.000442	0.00482	CcSEcCtD
Eletriptan—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00044	0.0048	CcSEcCtD
Eletriptan—Polyuria—Capecitabine—esophageal cancer	0.000436	0.00475	CcSEcCtD
Eletriptan—Skin discolouration—Methotrexate—esophageal cancer	0.000434	0.00474	CcSEcCtD
Eletriptan—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000432	0.0047	CcSEcCtD
Eletriptan—Abdominal discomfort—Cisplatin—esophageal cancer	0.00043	0.00469	CcSEcCtD
Eletriptan—Vascular purpura—Capecitabine—esophageal cancer	0.000428	0.00466	CcSEcCtD
Eletriptan—Glossitis—Methotrexate—esophageal cancer	0.000426	0.00464	CcSEcCtD
Eletriptan—Eye pain—Capecitabine—esophageal cancer	0.000424	0.00462	CcSEcCtD
Eletriptan—Increased appetite—Capecitabine—esophageal cancer	0.000407	0.00444	CcSEcCtD
Eletriptan—Amnesia—Capecitabine—esophageal cancer	0.000407	0.00444	CcSEcCtD
Eletriptan—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000406	0.00442	CcSEcCtD
Eletriptan—Atrial fibrillation—Capecitabine—esophageal cancer	0.000404	0.0044	CcSEcCtD
Eletriptan—Thirst—Capecitabine—esophageal cancer	0.000402	0.00438	CcSEcCtD
Eletriptan—Purpura—Capecitabine—esophageal cancer	0.000397	0.00433	CcSEcCtD
Eletriptan—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000394	0.0043	CcSEcCtD
Eletriptan—Arthritis—Capecitabine—esophageal cancer	0.000394	0.00429	CcSEcCtD
Eletriptan—Vaginal inflammation—Methotrexate—esophageal cancer	0.000392	0.00428	CcSEcCtD
Eletriptan—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000392	0.00427	CcSEcCtD
Eletriptan—Myocardial infarction—Cisplatin—esophageal cancer	0.000392	0.00427	CcSEcCtD
Eletriptan—Stomatitis—Cisplatin—esophageal cancer	0.00039	0.00425	CcSEcCtD
Eletriptan—Conjunctivitis—Cisplatin—esophageal cancer	0.000389	0.00424	CcSEcCtD
Eletriptan—Osteoarthritis—Capecitabine—esophageal cancer	0.000383	0.00417	CcSEcCtD
Eletriptan—Diplopia—Capecitabine—esophageal cancer	0.000383	0.00417	CcSEcCtD
Eletriptan—Depressed level of consciousness—Methotrexate—esophageal cancer	0.000379	0.00413	CcSEcCtD
Eletriptan—Migraine—Capecitabine—esophageal cancer	0.000377	0.00411	CcSEcCtD
Eletriptan—Vaginal infection—Methotrexate—esophageal cancer	0.00037	0.00404	CcSEcCtD
Eletriptan—Face oedema—Capecitabine—esophageal cancer	0.000369	0.00403	CcSEcCtD
Eletriptan—Bradycardia—Cisplatin—esophageal cancer	0.000366	0.00399	CcSEcCtD
Eletriptan—Mood swings—Capecitabine—esophageal cancer	0.000362	0.00395	CcSEcCtD
Eletriptan—Ataxia—Capecitabine—esophageal cancer	0.00036	0.00392	CcSEcCtD
Eletriptan—Urine output increased—Methotrexate—esophageal cancer	0.000355	0.00387	CcSEcCtD
Eletriptan—Urinary tract disorder—Cisplatin—esophageal cancer	0.000355	0.00387	CcSEcCtD
Eletriptan—Liver function test abnormal—Capecitabine—esophageal cancer	0.000353	0.00385	CcSEcCtD
Eletriptan—Urethral disorder—Cisplatin—esophageal cancer	0.000352	0.00384	CcSEcCtD
Eletriptan—Dry skin—Capecitabine—esophageal cancer	0.000351	0.00382	CcSEcCtD
Eletriptan—Abdominal pain upper—Capecitabine—esophageal cancer	0.000349	0.00381	CcSEcCtD
Eletriptan—Visual impairment—Cisplatin—esophageal cancer	0.000346	0.00377	CcSEcCtD
Eletriptan—Gastritis—Capecitabine—esophageal cancer	0.000339	0.00369	CcSEcCtD
Eletriptan—Muscular weakness—Capecitabine—esophageal cancer	0.000337	0.00368	CcSEcCtD
Eletriptan—Tinnitus—Cisplatin—esophageal cancer	0.000335	0.00365	CcSEcCtD
Eletriptan—Lymphadenopathy—Methotrexate—esophageal cancer	0.000334	0.00364	CcSEcCtD
Eletriptan—Flushing—Cisplatin—esophageal cancer	0.000333	0.00363	CcSEcCtD
Eletriptan—Abdominal distension—Capecitabine—esophageal cancer	0.000333	0.00363	CcSEcCtD
Eletriptan—Asthma—Capecitabine—esophageal cancer	0.000331	0.00361	CcSEcCtD
Eletriptan—Influenza—Capecitabine—esophageal cancer	0.000331	0.00361	CcSEcCtD
Eletriptan—Dysphagia—Capecitabine—esophageal cancer	0.000331	0.00361	CcSEcCtD
Eletriptan—Thrombophlebitis—Methotrexate—esophageal cancer	0.000329	0.00359	CcSEcCtD
Eletriptan—Polyuria—Methotrexate—esophageal cancer	0.000324	0.00354	CcSEcCtD
Eletriptan—Immune system disorder—Cisplatin—esophageal cancer	0.000324	0.00354	CcSEcCtD
Eletriptan—Angina pectoris—Capecitabine—esophageal cancer	0.000322	0.00351	CcSEcCtD
Eletriptan—Arrhythmia—Cisplatin—esophageal cancer	0.000321	0.0035	CcSEcCtD
Eletriptan—Bronchitis—Capecitabine—esophageal cancer	0.000318	0.00347	CcSEcCtD
Eletriptan—Alopecia—Cisplatin—esophageal cancer	0.000317	0.00346	CcSEcCtD
Eletriptan—Abdominal discomfort—Capecitabine—esophageal cancer	0.000317	0.00346	CcSEcCtD
Eletriptan—Flatulence—Cisplatin—esophageal cancer	0.000308	0.00336	CcSEcCtD
Eletriptan—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000302	0.00329	CcSEcCtD
Eletriptan—Weight increased—Capecitabine—esophageal cancer	0.000301	0.00328	CcSEcCtD
Eletriptan—Muscle spasms—Cisplatin—esophageal cancer	0.000301	0.00328	CcSEcCtD
Eletriptan—Weight decreased—Capecitabine—esophageal cancer	0.000299	0.00326	CcSEcCtD
Eletriptan—Hyperglycaemia—Capecitabine—esophageal cancer	0.000298	0.00325	CcSEcCtD
Eletriptan—Tremor—Cisplatin—esophageal cancer	0.000293	0.00319	CcSEcCtD
Eletriptan—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000291	0.00317	CcSEcCtD
Eletriptan—Ill-defined disorder—Cisplatin—esophageal cancer	0.00029	0.00316	CcSEcCtD
Eletriptan—Myocardial infarction—Capecitabine—esophageal cancer	0.000289	0.00315	CcSEcCtD
Eletriptan—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000289	0.00315	CcSEcCtD
Eletriptan—Anaemia—Cisplatin—esophageal cancer	0.000289	0.00315	CcSEcCtD
Eletriptan—Stomatitis—Capecitabine—esophageal cancer	0.000287	0.00313	CcSEcCtD
Eletriptan—Conjunctivitis—Capecitabine—esophageal cancer	0.000287	0.00312	CcSEcCtD
Eletriptan—Osteoarthritis—Methotrexate—esophageal cancer	0.000285	0.00311	CcSEcCtD
Eletriptan—Malaise—Cisplatin—esophageal cancer	0.000282	0.00307	CcSEcCtD
Eletriptan—Leukopenia—Cisplatin—esophageal cancer	0.00028	0.00305	CcSEcCtD
Eletriptan—Epistaxis—Capecitabine—esophageal cancer	0.000278	0.00303	CcSEcCtD
Eletriptan—Convulsion—Cisplatin—esophageal cancer	0.000271	0.00295	CcSEcCtD
Eletriptan—Mood swings—Methotrexate—esophageal cancer	0.00027	0.00294	CcSEcCtD
Eletriptan—Bradycardia—Capecitabine—esophageal cancer	0.000269	0.00294	CcSEcCtD
Eletriptan—Ataxia—Methotrexate—esophageal cancer	0.000268	0.00292	CcSEcCtD
Eletriptan—Myalgia—Cisplatin—esophageal cancer	0.000266	0.0029	CcSEcCtD
Eletriptan—Rhinitis—Capecitabine—esophageal cancer	0.000265	0.00289	CcSEcCtD
Eletriptan—Anxiety—Cisplatin—esophageal cancer	0.000265	0.00289	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000264	0.00288	CcSEcCtD
Eletriptan—Hypoaesthesia—Capecitabine—esophageal cancer	0.000263	0.00287	CcSEcCtD
Eletriptan—Liver function test abnormal—Methotrexate—esophageal cancer	0.000263	0.00287	CcSEcCtD
Eletriptan—Discomfort—Cisplatin—esophageal cancer	0.000263	0.00287	CcSEcCtD
Eletriptan—Pharyngitis—Capecitabine—esophageal cancer	0.000263	0.00286	CcSEcCtD
Eletriptan—Urinary tract disorder—Capecitabine—esophageal cancer	0.000261	0.00285	CcSEcCtD
Eletriptan—Oedema peripheral—Capecitabine—esophageal cancer	0.000261	0.00284	CcSEcCtD
Eletriptan—Urethral disorder—Capecitabine—esophageal cancer	0.000259	0.00283	CcSEcCtD
Eletriptan—Oedema—Cisplatin—esophageal cancer	0.000255	0.00278	CcSEcCtD
Eletriptan—Visual impairment—Capecitabine—esophageal cancer	0.000255	0.00278	CcSEcCtD
Eletriptan—Nervous system disorder—Cisplatin—esophageal cancer	0.00025	0.00273	CcSEcCtD
Eletriptan—Tachycardia—Cisplatin—esophageal cancer	0.000249	0.00271	CcSEcCtD
Eletriptan—Skin disorder—Cisplatin—esophageal cancer	0.000248	0.0027	CcSEcCtD
Eletriptan—Tinnitus—Capecitabine—esophageal cancer	0.000247	0.00269	CcSEcCtD
Eletriptan—Hyperhidrosis—Cisplatin—esophageal cancer	0.000247	0.00269	CcSEcCtD
Eletriptan—Asthma—Methotrexate—esophageal cancer	0.000246	0.00268	CcSEcCtD
Eletriptan—Flushing—Capecitabine—esophageal cancer	0.000246	0.00268	CcSEcCtD
Eletriptan—Anorexia—Cisplatin—esophageal cancer	0.000243	0.00265	CcSEcCtD
Eletriptan—Immune system disorder—Capecitabine—esophageal cancer	0.000239	0.00261	CcSEcCtD
Eletriptan—Hypotension—Cisplatin—esophageal cancer	0.000238	0.0026	CcSEcCtD
Eletriptan—Chills—Capecitabine—esophageal cancer	0.000238	0.00259	CcSEcCtD
Eletriptan—Arrhythmia—Capecitabine—esophageal cancer	0.000236	0.00258	CcSEcCtD
Eletriptan—Abdominal discomfort—Methotrexate—esophageal cancer	0.000236	0.00257	CcSEcCtD
Eletriptan—Alopecia—Capecitabine—esophageal cancer	0.000234	0.00255	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000232	0.00253	CcSEcCtD
Eletriptan—Paraesthesia—Cisplatin—esophageal cancer	0.000229	0.0025	CcSEcCtD
Eletriptan—Dyspnoea—Cisplatin—esophageal cancer	0.000227	0.00248	CcSEcCtD
Eletriptan—Flatulence—Capecitabine—esophageal cancer	0.000227	0.00248	CcSEcCtD
Eletriptan—Erectile dysfunction—Methotrexate—esophageal cancer	0.000227	0.00247	CcSEcCtD
Eletriptan—Dysgeusia—Capecitabine—esophageal cancer	0.000226	0.00246	CcSEcCtD
Eletriptan—Back pain—Capecitabine—esophageal cancer	0.000223	0.00243	CcSEcCtD
Eletriptan—Decreased appetite—Cisplatin—esophageal cancer	0.000222	0.00242	CcSEcCtD
Eletriptan—Muscle spasms—Capecitabine—esophageal cancer	0.000222	0.00242	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00022	0.0024	CcSEcCtD
Eletriptan—Drowsiness—Methotrexate—esophageal cancer	0.00022	0.00239	CcSEcCtD
Eletriptan—Pain—Cisplatin—esophageal cancer	0.000218	0.00238	CcSEcCtD
Eletriptan—Tremor—Capecitabine—esophageal cancer	0.000216	0.00235	CcSEcCtD
Eletriptan—Stomatitis—Methotrexate—esophageal cancer	0.000214	0.00233	CcSEcCtD
Eletriptan—Ill-defined disorder—Capecitabine—esophageal cancer	0.000214	0.00233	CcSEcCtD
Eletriptan—Conjunctivitis—Methotrexate—esophageal cancer	0.000213	0.00233	CcSEcCtD
Eletriptan—Anaemia—Capecitabine—esophageal cancer	0.000213	0.00232	CcSEcCtD
Eletriptan—Sweating—Methotrexate—esophageal cancer	0.00021	0.00229	CcSEcCtD
Eletriptan—Feeling abnormal—Cisplatin—esophageal cancer	0.00021	0.00229	CcSEcCtD
Eletriptan—Malaise—Capecitabine—esophageal cancer	0.000208	0.00227	CcSEcCtD
Eletriptan—Epistaxis—Methotrexate—esophageal cancer	0.000207	0.00226	CcSEcCtD
Eletriptan—Vertigo—Capecitabine—esophageal cancer	0.000207	0.00226	CcSEcCtD
Eletriptan—Syncope—Capecitabine—esophageal cancer	0.000207	0.00225	CcSEcCtD
Eletriptan—Leukopenia—Capecitabine—esophageal cancer	0.000206	0.00225	CcSEcCtD
Eletriptan—Palpitations—Capecitabine—esophageal cancer	0.000204	0.00222	CcSEcCtD
Eletriptan—Loss of consciousness—Capecitabine—esophageal cancer	0.000203	0.00221	CcSEcCtD
Eletriptan—Body temperature increased—Cisplatin—esophageal cancer	0.000202	0.0022	CcSEcCtD
Eletriptan—Cough—Capecitabine—esophageal cancer	0.000201	0.00219	CcSEcCtD
Eletriptan—Hypertension—Capecitabine—esophageal cancer	0.000199	0.00217	CcSEcCtD
Eletriptan—Myalgia—Capecitabine—esophageal cancer	0.000196	0.00214	CcSEcCtD
Eletriptan—Arthralgia—Capecitabine—esophageal cancer	0.000196	0.00214	CcSEcCtD
Eletriptan—Pharyngitis—Methotrexate—esophageal cancer	0.000196	0.00213	CcSEcCtD
Eletriptan—Anxiety—Capecitabine—esophageal cancer	0.000196	0.00213	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000195	0.00212	CcSEcCtD
Eletriptan—Urinary tract disorder—Methotrexate—esophageal cancer	0.000195	0.00212	CcSEcCtD
Eletriptan—Discomfort—Capecitabine—esophageal cancer	0.000194	0.00211	CcSEcCtD
Eletriptan—Urethral disorder—Methotrexate—esophageal cancer	0.000193	0.00211	CcSEcCtD
Eletriptan—Dry mouth—Capecitabine—esophageal cancer	0.000192	0.00209	CcSEcCtD
Eletriptan—Visual impairment—Methotrexate—esophageal cancer	0.00019	0.00207	CcSEcCtD
Eletriptan—Confusional state—Capecitabine—esophageal cancer	0.00019	0.00207	CcSEcCtD
Eletriptan—Oedema—Capecitabine—esophageal cancer	0.000188	0.00205	CcSEcCtD
Eletriptan—Hypersensitivity—Cisplatin—esophageal cancer	0.000188	0.00205	CcSEcCtD
Eletriptan—Shock—Capecitabine—esophageal cancer	0.000185	0.00202	CcSEcCtD
Eletriptan—Nervous system disorder—Capecitabine—esophageal cancer	0.000184	0.00201	CcSEcCtD
Eletriptan—Tinnitus—Methotrexate—esophageal cancer	0.000184	0.002	CcSEcCtD
Eletriptan—Tachycardia—Capecitabine—esophageal cancer	0.000184	0.002	CcSEcCtD
Eletriptan—Asthenia—Cisplatin—esophageal cancer	0.000183	0.002	CcSEcCtD
Eletriptan—Skin disorder—Capecitabine—esophageal cancer	0.000183	0.00199	CcSEcCtD
Eletriptan—Hyperhidrosis—Capecitabine—esophageal cancer	0.000182	0.00198	CcSEcCtD
Eletriptan—Anorexia—Capecitabine—esophageal cancer	0.000179	0.00195	CcSEcCtD
Eletriptan—Immune system disorder—Methotrexate—esophageal cancer	0.000178	0.00194	CcSEcCtD
Eletriptan—Chills—Methotrexate—esophageal cancer	0.000177	0.00193	CcSEcCtD
Eletriptan—Hypotension—Capecitabine—esophageal cancer	0.000176	0.00192	CcSEcCtD
Eletriptan—Diarrhoea—Cisplatin—esophageal cancer	0.000175	0.0019	CcSEcCtD
Eletriptan—Alopecia—Methotrexate—esophageal cancer	0.000174	0.0019	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000171	0.00187	CcSEcCtD
Eletriptan—Insomnia—Capecitabine—esophageal cancer	0.00017	0.00185	CcSEcCtD
Eletriptan—Paraesthesia—Capecitabine—esophageal cancer	0.000169	0.00184	CcSEcCtD
Eletriptan—Dysgeusia—Methotrexate—esophageal cancer	0.000168	0.00183	CcSEcCtD
Eletriptan—Dyspnoea—Capecitabine—esophageal cancer	0.000168	0.00183	CcSEcCtD
Eletriptan—Back pain—Methotrexate—esophageal cancer	0.000166	0.00181	CcSEcCtD
Eletriptan—Dyspepsia—Capecitabine—esophageal cancer	0.000166	0.0018	CcSEcCtD
Eletriptan—Decreased appetite—Capecitabine—esophageal cancer	0.000163	0.00178	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000162	0.00177	CcSEcCtD
Eletriptan—Vomiting—Cisplatin—esophageal cancer	0.000162	0.00177	CcSEcCtD
Eletriptan—Fatigue—Capecitabine—esophageal cancer	0.000162	0.00177	CcSEcCtD
Eletriptan—Rash—Cisplatin—esophageal cancer	0.000161	0.00175	CcSEcCtD
Eletriptan—Constipation—Capecitabine—esophageal cancer	0.000161	0.00175	CcSEcCtD
Eletriptan—Pain—Capecitabine—esophageal cancer	0.000161	0.00175	CcSEcCtD
Eletriptan—Dermatitis—Cisplatin—esophageal cancer	0.000161	0.00175	CcSEcCtD
Eletriptan—HTR7—neck—esophageal cancer	0.000159	0.0623	CbGeAlD
Eletriptan—Ill-defined disorder—Methotrexate—esophageal cancer	0.000159	0.00174	CcSEcCtD
Eletriptan—Anaemia—Methotrexate—esophageal cancer	0.000159	0.00173	CcSEcCtD
Eletriptan—Feeling abnormal—Capecitabine—esophageal cancer	0.000155	0.00169	CcSEcCtD
Eletriptan—Malaise—Methotrexate—esophageal cancer	0.000155	0.00169	CcSEcCtD
Eletriptan—Vertigo—Methotrexate—esophageal cancer	0.000154	0.00168	CcSEcCtD
Eletriptan—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000154	0.00168	CcSEcCtD
Eletriptan—Leukopenia—Methotrexate—esophageal cancer	0.000154	0.00167	CcSEcCtD
Eletriptan—Nausea—Cisplatin—esophageal cancer	0.000152	0.00165	CcSEcCtD
Eletriptan—Cough—Methotrexate—esophageal cancer	0.00015	0.00163	CcSEcCtD
Eletriptan—Urticaria—Capecitabine—esophageal cancer	0.000149	0.00163	CcSEcCtD
Eletriptan—Abdominal pain—Capecitabine—esophageal cancer	0.000149	0.00162	CcSEcCtD
Eletriptan—Body temperature increased—Capecitabine—esophageal cancer	0.000149	0.00162	CcSEcCtD
Eletriptan—Convulsion—Methotrexate—esophageal cancer	0.000149	0.00162	CcSEcCtD
Eletriptan—Arthralgia—Methotrexate—esophageal cancer	0.000146	0.00159	CcSEcCtD
Eletriptan—Myalgia—Methotrexate—esophageal cancer	0.000146	0.00159	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000145	0.00158	CcSEcCtD
Eletriptan—Discomfort—Methotrexate—esophageal cancer	0.000144	0.00157	CcSEcCtD
Eletriptan—Confusional state—Methotrexate—esophageal cancer	0.000141	0.00154	CcSEcCtD
Eletriptan—Hypersensitivity—Capecitabine—esophageal cancer	0.000139	0.00151	CcSEcCtD
Eletriptan—Nervous system disorder—Methotrexate—esophageal cancer	0.000137	0.0015	CcSEcCtD
Eletriptan—Skin disorder—Methotrexate—esophageal cancer	0.000136	0.00148	CcSEcCtD
Eletriptan—Hyperhidrosis—Methotrexate—esophageal cancer	0.000135	0.00148	CcSEcCtD
Eletriptan—Asthenia—Capecitabine—esophageal cancer	0.000135	0.00147	CcSEcCtD
Eletriptan—Anorexia—Methotrexate—esophageal cancer	0.000133	0.00145	CcSEcCtD
Eletriptan—Pruritus—Capecitabine—esophageal cancer	0.000133	0.00145	CcSEcCtD
Eletriptan—Hypotension—Methotrexate—esophageal cancer	0.000131	0.00143	CcSEcCtD
Eletriptan—Diarrhoea—Capecitabine—esophageal cancer	0.000129	0.0014	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000128	0.00139	CcSEcCtD
Eletriptan—Insomnia—Methotrexate—esophageal cancer	0.000127	0.00138	CcSEcCtD
Eletriptan—Paraesthesia—Methotrexate—esophageal cancer	0.000126	0.00137	CcSEcCtD
Eletriptan—Dyspnoea—Methotrexate—esophageal cancer	0.000125	0.00136	CcSEcCtD
Eletriptan—Somnolence—Methotrexate—esophageal cancer	0.000124	0.00136	CcSEcCtD
Eletriptan—Dizziness—Capecitabine—esophageal cancer	0.000124	0.00136	CcSEcCtD
Eletriptan—Dyspepsia—Methotrexate—esophageal cancer	0.000123	0.00134	CcSEcCtD
Eletriptan—HTR2B—smooth muscle tissue—esophageal cancer	0.000122	0.0477	CbGeAlD
Eletriptan—Decreased appetite—Methotrexate—esophageal cancer	0.000122	0.00133	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000121	0.00132	CcSEcCtD
Eletriptan—Fatigue—Methotrexate—esophageal cancer	0.000121	0.00132	CcSEcCtD
Eletriptan—Pain—Methotrexate—esophageal cancer	0.00012	0.00131	CcSEcCtD
Eletriptan—Vomiting—Capecitabine—esophageal cancer	0.00012	0.0013	CcSEcCtD
Eletriptan—Rash—Capecitabine—esophageal cancer	0.000119	0.00129	CcSEcCtD
Eletriptan—Dermatitis—Capecitabine—esophageal cancer	0.000118	0.00129	CcSEcCtD
Eletriptan—Headache—Capecitabine—esophageal cancer	0.000118	0.00128	CcSEcCtD
Eletriptan—Feeling abnormal—Methotrexate—esophageal cancer	0.000115	0.00126	CcSEcCtD
Eletriptan—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000114	0.00125	CcSEcCtD
Eletriptan—Nausea—Capecitabine—esophageal cancer	0.000112	0.00122	CcSEcCtD
Eletriptan—Urticaria—Methotrexate—esophageal cancer	0.000111	0.00121	CcSEcCtD
Eletriptan—Abdominal pain—Methotrexate—esophageal cancer	0.000111	0.00121	CcSEcCtD
Eletriptan—Body temperature increased—Methotrexate—esophageal cancer	0.000111	0.00121	CcSEcCtD
Eletriptan—HTR7—epithelium—esophageal cancer	0.000108	0.0424	CbGeAlD
Eletriptan—CYP2A6—lung—esophageal cancer	0.000105	0.0409	CbGeAlD
Eletriptan—HTR7—smooth muscle tissue—esophageal cancer	0.000105	0.0408	CbGeAlD
Eletriptan—Hypersensitivity—Methotrexate—esophageal cancer	0.000103	0.00112	CcSEcCtD
Eletriptan—Asthenia—Methotrexate—esophageal cancer	0.0001	0.0011	CcSEcCtD
Eletriptan—Pruritus—Methotrexate—esophageal cancer	9.91e-05	0.00108	CcSEcCtD
Eletriptan—HTR2B—digestive system—esophageal cancer	9.64e-05	0.0377	CbGeAlD
Eletriptan—HTR7—trachea—esophageal cancer	9.59e-05	0.0375	CbGeAlD
Eletriptan—Diarrhoea—Methotrexate—esophageal cancer	9.58e-05	0.00104	CcSEcCtD
Eletriptan—Dizziness—Methotrexate—esophageal cancer	9.26e-05	0.00101	CcSEcCtD
Eletriptan—Vomiting—Methotrexate—esophageal cancer	8.9e-05	0.00097	CcSEcCtD
Eletriptan—Rash—Methotrexate—esophageal cancer	8.83e-05	0.000962	CcSEcCtD
Eletriptan—Dermatitis—Methotrexate—esophageal cancer	8.82e-05	0.000961	CcSEcCtD
Eletriptan—Headache—Methotrexate—esophageal cancer	8.77e-05	0.000956	CcSEcCtD
Eletriptan—Nausea—Methotrexate—esophageal cancer	8.32e-05	0.000907	CcSEcCtD
Eletriptan—HTR7—digestive system—esophageal cancer	8.25e-05	0.0323	CbGeAlD
Eletriptan—CYP2C19—digestive system—esophageal cancer	8.06e-05	0.0315	CbGeAlD
Eletriptan—HTR2B—lung—esophageal cancer	8.05e-05	0.0315	CbGeAlD
Eletriptan—PTGS1—epithelium—esophageal cancer	7.5e-05	0.0293	CbGeAlD
Eletriptan—PTGS1—smooth muscle tissue—esophageal cancer	7.22e-05	0.0282	CbGeAlD
Eletriptan—HTR7—lung—esophageal cancer	6.89e-05	0.0269	CbGeAlD
Eletriptan—PTGS1—trachea—esophageal cancer	6.63e-05	0.0259	CbGeAlD
Eletriptan—CYP2C9—digestive system—esophageal cancer	6.25e-05	0.0244	CbGeAlD
Eletriptan—PTGS1—digestive system—esophageal cancer	5.7e-05	0.0223	CbGeAlD
Eletriptan—HTR2B—lymph node—esophageal cancer	5.5e-05	0.0215	CbGeAlD
Eletriptan—CYP3A4—digestive system—esophageal cancer	4.76e-05	0.0186	CbGeAlD
Eletriptan—PTGS1—lung—esophageal cancer	4.76e-05	0.0186	CbGeAlD
Eletriptan—CYP2D6—digestive system—esophageal cancer	4.69e-05	0.0183	CbGeAlD
Eletriptan—ABCB1—epithelium—esophageal cancer	4.43e-05	0.0173	CbGeAlD
Eletriptan—ABCB1—trachea—esophageal cancer	3.92e-05	0.0153	CbGeAlD
Eletriptan—ABCB1—digestive system—esophageal cancer	3.37e-05	0.0132	CbGeAlD
Eletriptan—PTGS1—lymph node—esophageal cancer	3.26e-05	0.0127	CbGeAlD
Eletriptan—ABCB1—lung—esophageal cancer	2.82e-05	0.011	CbGeAlD
Eletriptan—ABCB1—lymph node—esophageal cancer	1.93e-05	0.00753	CbGeAlD
Eletriptan—ABCB1—Metabolism—GSTO1—esophageal cancer	1.53e-05	0.000161	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ALOX15—esophageal cancer	1.51e-05	0.000159	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ALDOB—esophageal cancer	1.5e-05	0.000158	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—NOS3—esophageal cancer	1.5e-05	0.000158	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ALOX15—esophageal cancer	1.5e-05	0.000158	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—CYP19A1—esophageal cancer	1.49e-05	0.000157	CbGpPWpGaD
Eletriptan—HTR1E—GPCR downstream signaling—PIK3CA—esophageal cancer	1.49e-05	0.000157	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—SMAD4—esophageal cancer	1.48e-05	0.000156	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ALDOB—esophageal cancer	1.47e-05	0.000155	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.46e-05	0.000154	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CA1—esophageal cancer	1.46e-05	0.000154	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GAPDH—esophageal cancer	1.45e-05	0.000152	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GSTO1—esophageal cancer	1.44e-05	0.000152	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—TPI1—esophageal cancer	1.44e-05	0.000152	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—HMOX1—esophageal cancer	1.44e-05	0.000152	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CRABP1—esophageal cancer	1.44e-05	0.000151	CbGpPWpGaD
Eletriptan—HTR1F—Signaling by GPCR—PIK3CA—esophageal cancer	1.43e-05	0.000151	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—TPI1—esophageal cancer	1.43e-05	0.000151	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GSTO1—esophageal cancer	1.43e-05	0.000151	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NOTCH2—esophageal cancer	1.43e-05	0.00015	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—NOS3—esophageal cancer	1.42e-05	0.000149	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.42e-05	0.000149	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GAPDH—esophageal cancer	1.41e-05	0.000149	CbGpPWpGaD
Eletriptan—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.41e-05	0.000149	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—ERBB2—esophageal cancer	1.41e-05	0.000148	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CRABP1—esophageal cancer	1.4e-05	0.000148	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—ABCB1—esophageal cancer	1.38e-05	0.000146	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ALDOB—esophageal cancer	1.38e-05	0.000146	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.37e-05	0.000144	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GNG7—esophageal cancer	1.37e-05	0.000144	CbGpPWpGaD
Eletriptan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.36e-05	0.000144	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—HMOX1—esophageal cancer	1.36e-05	0.000144	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—PIK3CA—esophageal cancer	1.35e-05	0.000142	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CA2—esophageal cancer	1.34e-05	0.000141	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GNG7—esophageal cancer	1.33e-05	0.00014	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GAPDH—esophageal cancer	1.33e-05	0.00014	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—ERBB2—esophageal cancer	1.33e-05	0.00014	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—HIF1A—esophageal cancer	1.32e-05	0.000139	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.32e-05	0.000139	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CRABP1—esophageal cancer	1.32e-05	0.000139	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—HIF1A—esophageal cancer	1.32e-05	0.000138	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—ABCB1—esophageal cancer	1.31e-05	0.000138	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.31e-05	0.000138	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—HIF1A—esophageal cancer	1.29e-05	0.000136	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ALDH2—esophageal cancer	1.28e-05	0.000135	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TGFBR2—esophageal cancer	1.27e-05	0.000133	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—KDR—esophageal cancer	1.27e-05	0.000133	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—KDR—esophageal cancer	1.26e-05	0.000132	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GNG7—esophageal cancer	1.26e-05	0.000132	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ALDH2—esophageal cancer	1.25e-05	0.000131	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.25e-05	0.000131	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ADH7—esophageal cancer	1.25e-05	0.000131	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GNG7—esophageal cancer	1.24e-05	0.000131	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CCND1—esophageal cancer	1.24e-05	0.000131	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—KDR—esophageal cancer	1.23e-05	0.00013	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GSTT1—esophageal cancer	1.22e-05	0.000128	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—HIF1A—esophageal cancer	1.21e-05	0.000127	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CYP2A6—esophageal cancer	1.2e-05	0.000127	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CDKN1A—esophageal cancer	1.2e-05	0.000127	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—SMAD4—esophageal cancer	1.2e-05	0.000126	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.2e-05	0.000126	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—NOTCH1—esophageal cancer	1.19e-05	0.000126	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GSTT1—esophageal cancer	1.19e-05	0.000125	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—NOTCH1—esophageal cancer	1.18e-05	0.000125	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ALDH2—esophageal cancer	1.18e-05	0.000124	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.17e-05	0.000124	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CCND1—esophageal cancer	1.17e-05	0.000123	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.17e-05	0.000123	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—NOTCH1—esophageal cancer	1.16e-05	0.000122	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—KDR—esophageal cancer	1.16e-05	0.000122	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—EP300—esophageal cancer	1.14e-05	0.00012	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTGS1—esophageal cancer	1.14e-05	0.00012	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ENO1—esophageal cancer	1.14e-05	0.00012	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CDKN1A—esophageal cancer	1.13e-05	0.000119	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PSME1—esophageal cancer	1.12e-05	0.000118	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PSME2—esophageal cancer	1.12e-05	0.000118	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GSTT1—esophageal cancer	1.12e-05	0.000118	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ENO1—esophageal cancer	1.11e-05	0.000117	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTGS1—esophageal cancer	1.11e-05	0.000117	CbGpPWpGaD
Eletriptan—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.11e-05	0.000117	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.11e-05	0.000117	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CYP2A6—esophageal cancer	1.11e-05	0.000116	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.1e-05	0.000115	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PSME2—esophageal cancer	1.1e-05	0.000115	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PSME1—esophageal cancer	1.1e-05	0.000115	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.09e-05	0.000115	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.09e-05	0.000115	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—NOTCH1—esophageal cancer	1.09e-05	0.000115	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CREBBP—esophageal cancer	1.08e-05	0.000114	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—EP300—esophageal cancer	1.08e-05	0.000114	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CREBBP—esophageal cancer	1.07e-05	0.000113	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—EGFR—esophageal cancer	1.06e-05	0.000112	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—EGFR—esophageal cancer	1.06e-05	0.000111	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CREBBP—esophageal cancer	1.05e-05	0.000111	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.05e-05	0.00011	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ENO1—esophageal cancer	1.05e-05	0.00011	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.05e-05	0.00011	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—TYMP—esophageal cancer	1.04e-05	0.00011	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.04e-05	0.000109	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ENO1—esophageal cancer	1.04e-05	0.000109	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—EGFR—esophageal cancer	1.03e-05	0.000109	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PSME1—esophageal cancer	1.03e-05	0.000109	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PSME2—esophageal cancer	1.03e-05	0.000109	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PSME2—esophageal cancer	1.02e-05	0.000108	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PSME1—esophageal cancer	1.02e-05	0.000108	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—PIK3CA—esophageal cancer	1.02e-05	0.000107	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.01e-05	0.000107	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—PIK3CA—esophageal cancer	1.01e-05	0.000106	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—MYC—esophageal cancer	9.97e-06	0.000105	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ALOX15—esophageal cancer	9.89e-06	0.000104	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CREBBP—esophageal cancer	9.88e-06	0.000104	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—PIK3CA—esophageal cancer	9.88e-06	0.000104	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	9.81e-06	0.000103	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	9.81e-06	0.000103	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—EGFR—esophageal cancer	9.75e-06	0.000103	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—EGFR—esophageal cancer	9.71e-06	0.000102	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CYP1B1—esophageal cancer	9.69e-06	0.000102	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—NOS3—esophageal cancer	9.68e-06	0.000102	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—NOS3—esophageal cancer	9.62e-06	0.000101	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CYP1B1—esophageal cancer	9.46e-06	9.96e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—TPI1—esophageal cancer	9.44e-06	9.94e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTO1—esophageal cancer	9.44e-06	9.94e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—NOS3—esophageal cancer	9.42e-06	9.92e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—MYC—esophageal cancer	9.4e-06	9.9e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—KDR—esophageal cancer	9.38e-06	9.88e-05	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—PIK3CA—esophageal cancer	9.28e-06	9.77e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—CREBBP—esophageal cancer	9.25e-06	9.75e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—PIK3CA—esophageal cancer	9.22e-06	9.71e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—EGFR—esophageal cancer	9.2e-06	9.69e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—PIK3CA—esophageal cancer	9.16e-06	9.65e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CYP19A1—esophageal cancer	9.11e-06	9.6e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—ERBB2—esophageal cancer	9.05e-06	9.53e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ALDOB—esophageal cancer	9.05e-06	9.53e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—ERBB2—esophageal cancer	9e-06	9.47e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—PIK3CA—esophageal cancer	8.97e-06	9.45e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.95e-06	9.42e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CYP1B1—esophageal cancer	8.92e-06	9.39e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CYP19A1—esophageal cancer	8.9e-06	9.37e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—NOS3—esophageal cancer	8.85e-06	9.32e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CYP1B1—esophageal cancer	8.84e-06	9.31e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	8.84e-06	9.31e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—ERBB2—esophageal cancer	8.81e-06	9.28e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—CREBBP—esophageal cancer	8.75e-06	9.22e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GAPDH—esophageal cancer	8.71e-06	9.17e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CRABP1—esophageal cancer	8.63e-06	9.09e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—PIK3CA—esophageal cancer	8.46e-06	8.91e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—PIK3CA—esophageal cancer	8.43e-06	8.87e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CYP19A1—esophageal cancer	8.38e-06	8.83e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—HMOX1—esophageal cancer	8.32e-06	8.76e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CYP19A1—esophageal cancer	8.31e-06	8.75e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—NOS3—esophageal cancer	8.29e-06	8.73e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—ERBB2—esophageal cancer	8.27e-06	8.71e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GNG7—esophageal cancer	8.21e-06	8.64e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—TP53—esophageal cancer	8.19e-06	8.62e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.16e-06	8.59e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—HMOX1—esophageal cancer	8.12e-06	8.55e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	8.01e-06	8.44e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCND1—esophageal cancer	8e-06	8.42e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ABCB1—esophageal cancer	7.98e-06	8.41e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—PIK3CA—esophageal cancer	7.98e-06	8.41e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCND1—esophageal cancer	7.95e-06	8.37e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	7.87e-06	8.29e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—NOS3—esophageal cancer	7.84e-06	8.25e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCND1—esophageal cancer	7.78e-06	8.19e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CDKN1A—esophageal cancer	7.74e-06	8.15e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—TP53—esophageal cancer	7.72e-06	8.13e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ALDH2—esophageal cancer	7.69e-06	8.1e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	7.69e-06	8.1e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—HMOX1—esophageal cancer	7.65e-06	8.06e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—HMOX1—esophageal cancer	7.58e-06	7.99e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTGS2—esophageal cancer	7.58e-06	7.98e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	7.53e-06	7.93e-05	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	7.52e-06	7.92e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.44e-06	7.83e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—EP300—esophageal cancer	7.36e-06	7.75e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ABCB1—esophageal cancer	7.34e-06	7.73e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTT1—esophageal cancer	7.32e-06	7.7e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—EP300—esophageal cancer	7.32e-06	7.7e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCND1—esophageal cancer	7.31e-06	7.7e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ABCB1—esophageal cancer	7.28e-06	7.67e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP2A6—esophageal cancer	7.23e-06	7.62e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NOS3—esophageal cancer	7.17e-06	7.55e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTGS2—esophageal cancer	7.17e-06	7.55e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—EP300—esophageal cancer	7.16e-06	7.54e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	7.07e-06	7.45e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ENO1—esophageal cancer	6.86e-06	7.22e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTGS1—esophageal cancer	6.86e-06	7.22e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	6.83e-06	7.2e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PSME1—esophageal cancer	6.76e-06	7.11e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PSME2—esophageal cancer	6.76e-06	7.11e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—EP300—esophageal cancer	6.73e-06	7.09e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	6.71e-06	7.07e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MYC—esophageal cancer	6.42e-06	6.76e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MYC—esophageal cancer	6.37e-06	6.71e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—EP300—esophageal cancer	6.3e-06	6.64e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—EGFR—esophageal cancer	6.28e-06	6.61e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MYC—esophageal cancer	6.24e-06	6.57e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—EGFR—esophageal cancer	6.24e-06	6.57e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—EGFR—esophageal cancer	6.11e-06	6.43e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.04e-06	6.36e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—EP300—esophageal cancer	5.96e-06	6.28e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCND1—esophageal cancer	5.93e-06	6.24e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MYC—esophageal cancer	5.86e-06	6.17e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP1B1—esophageal cancer	5.83e-06	6.14e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—EGFR—esophageal cancer	5.74e-06	6.04e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	5.73e-06	6.04e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.5e-06	5.8e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP19A1—esophageal cancer	5.48e-06	5.77e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EP300—esophageal cancer	5.46e-06	5.75e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PIK3CA—esophageal cancer	5.45e-06	5.74e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	5.41e-06	5.7e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CREBBP—esophageal cancer	5.34e-06	5.62e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	5.3e-06	5.58e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TP53—esophageal cancer	5.27e-06	5.55e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TP53—esophageal cancer	5.24e-06	5.51e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CREBBP—esophageal cancer	5.21e-06	5.48e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TP53—esophageal cancer	5.13e-06	5.4e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—HMOX1—esophageal cancer	5e-06	5.27e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	4.98e-06	5.24e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CREBBP—esophageal cancer	4.91e-06	5.17e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CREBBP—esophageal cancer	4.86e-06	5.12e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TP53—esophageal cancer	4.82e-06	5.07e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ABCB1—esophageal cancer	4.8e-06	5.06e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—NOS3—esophageal cancer	4.78e-06	5.03e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MYC—esophageal cancer	4.76e-06	5.01e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—NOS3—esophageal cancer	4.66e-06	4.91e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CA—esophageal cancer	4.66e-06	4.91e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EGFR—esophageal cancer	4.65e-06	4.9e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CA—esophageal cancer	4.41e-06	4.64e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—NOS3—esophageal cancer	4.39e-06	4.63e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTGS2—esophageal cancer	4.37e-06	4.6e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—NOS3—esophageal cancer	4.36e-06	4.59e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTGS2—esophageal cancer	4.26e-06	4.49e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	4.04e-06	4.25e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTGS2—esophageal cancer	4.02e-06	4.23e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTGS2—esophageal cancer	3.98e-06	4.2e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TP53—esophageal cancer	3.9e-06	4.11e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—EP300—esophageal cancer	3.63e-06	3.83e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—EP300—esophageal cancer	3.55e-06	3.73e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—EP300—esophageal cancer	3.34e-06	3.52e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—EP300—esophageal cancer	3.31e-06	3.49e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.21e-06	3.38e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NOS3—esophageal cancer	2.87e-06	3.03e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CA—esophageal cancer	2.69e-06	2.83e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.63e-06	2.77e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.62e-06	2.76e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2.47e-06	2.6e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CA—esophageal cancer	2.45e-06	2.58e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—EP300—esophageal cancer	2.19e-06	2.3e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.62e-06	1.7e-05	CbGpPWpGaD
